Lobular Carcinomas Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.

TitleLobular Carcinomas Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.
Publication TypeJournal Article
Year of Publication2019
AuthorsLee JYoun, Schizas M, Geyer FC, Selenica P, Piscuoglio S, Sakr RA, K Y Ng C, Carniello JVScarpa, Towers R, Giri DD, de Andrade VP, Papanastasiou AD, Viale A, Harris RS, Solit DB, Weigelt B, Reis-Filho JS, King TA
JournalClin Cancer Res
Volume25
Issue2
Pagination674-686
Date Published2019 01 15
ISSN1557-3265
KeywordsBreast Carcinoma In Situ, Carcinoma, Lobular, Clonal Evolution, Disease Progression, Genetic Heterogeneity, Genetic Variation, High-Throughput Nucleotide Sequencing, Humans, Mutation, Neoplasm Metastasis, Neoplasm Staging, Tumor Burden, Whole Exome Sequencing
Abstract

PURPOSE: Lobular carcinoma (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers. We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational methods.

RESULTS: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for ILCs, with mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found to be clonally related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of clonal selection and/or parallel/branched progression. Intralesion genetic heterogeneity was higher among LCIS clonally related to DCIS/ILC than in those nonclonally related to DCIS/ILC. A shift from aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS and/or ILC in a subset of cases.

CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a nonobligate precursor of breast cancer. Intralesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions.

DOI10.1158/1078-0432.CCR-18-1103
Alternate JournalClin Cancer Res
PubMed ID30185420
PubMed Central IDPMC6726436
Grant ListP30 CA008748 / CA / NCI NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
Related Faculty: 
Jose Scarpa Carniello, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700